LIF and neoplasm: Inhibition of LIF signaling by genetic LIFR deletion, LIF knockdown, or treatment with LIF neutralizing monoclonal antibodies leads to a reduction in tumor progression in mouse PDAC models and decreases tumor engraftment and growth in PDAC xenograft models [62,63].